Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Hildebrand

Optometrist Arlington, TX Doctor of Optometry

NPI 1932677101 CMS profile 5696177

350 E Interstate 20, Arlington, TX 76018

Open in the dashboard

General payments

$6,111

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Hildebrand of Arlington, TX is reported in the CMS Open Payments database as having received $6,111 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $818 26
2024 General $485 16
2023 General $1,284 47
2022 General $1,364 35
2021 General $841 20
2020 General $516 16
2019 General $803 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Hildebrand
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Matthew Hildebrand were reported at $818. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Matthew Hildebrand Optometrist median Middle half National median
2019 $803 $159 $67–$371 $163
2020 $516 $72 $29–$165 $114
2021 $841 $125 $46–$292 $132
2022 $1,364 $162 $66–$374 $149
2023 $1,284 $177 $72–$406 $160
2024 $485 $188 $77–$427 $164
2025 $818 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $930 35 payments
  2. Bausch & Lomb Americas Inc. $858 20 payments
  3. Sun Pharmaceutical Industries Inc. $644 19 payments
  4. Alcon Vision LLC $520 14 payments
  5. AbbVie, Inc. $507 23 payments
  6. Allergan Inc. $501 16 payments
  7. Eyevance Pharmaceuticals LLC $319 5 payments
  8. Aerie Pharmaceuticals, Inc. $257 3 payments
  9. Johnson & Johnson Surgical Vision, Inc. $242 2 payments
  10. TissueTech, Inc. $231 4 payments
  11. Other $1,101 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,104 173 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. XIIDRA $796 37 payments
  2. Cequa $644 19 payments
  3. MIEBO $482 11 payments
  4. RESTASIS $406 10 payments
  5. LUMIGAN $379 15 payments
  6. rhopressa $344 4 payments
  7. rocklatan $344 4 payments
  8. VYZULTA $341 8 payments
  9. PROKERA $231 4 payments
  10. AMNIOGRAFT $231 4 payments
  11. Other $3,347 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

942

Median for Optometry: 120

Drug cost

$231,785

Median for Optometry: $8,864

Branded share of claims

35.9%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 46 $61,709
Xiidra Lifitegrast Brand 33 $42,852
Lumigan Bimatoprost Brand 71 $37,501
Miebo Perfluorohexyloctane/Pf Brand 20 $28,206
Cequa Cyclosporine Brand 16 $14,329
Combigan Brimonidine Tartrate/Timolol Brand 26 $10,737
Cyclosporine Generic 22 $10,728
Tyrvaya Varenicline Tartrate Brand 14 $8,920
Travoprost Generic 28 $4,936
Latanoprost Generic 310 $3,500

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$44,856

Medicare's payments for the services billed

Medicare patients

371

Average age 74

Services billed

717

220 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 18%
Atrial fibrillation 17%
Cancer 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MIEBO
  • Bausch & Lomb Americas Inc. $211
$211 20 —
XIIDRA
  • Bausch & Lomb Americas Inc. $78
$78 33 —
LUMIGAN
  • AbbVie, Inc. $50
$50 71 —
VYZULTA
  • Bausch & Lomb Americas Inc. $42
$42 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $19
$19 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record